Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Sep 27, 2026, 1:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Intervention: Oral alprazolam 2 mg Clear all

Conditions: Panic Disorder
Interventions: placebo, alprazolam XR; Other · Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004
U.S. locations: 18
States / cities: Hialeah, Florida • Jacksonville, Florida • North Miami, Florida + 15 more

Conditions: Driving Behavior, Driving Under the Influence
Interventions: Placebo (Lactose) Capsule, 0.75 mg Alprazolam Capsule, Cannabis (6.18% THC / <0.025% CBD), Cannabis (0%/ THC / 0% CBD); Drug
Lead sponsor: Timothy L. Brown; Other
Eligibility: 19 Years to 45 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Healthy
Interventions: ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG, NIRAVAM TM 2 mg orally disintegrating tablets, single dose; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Abuse Liability of Staccato Alprazolam
Interventions: Inhaled placebo + oral placebo, Inhaled alprazolam 0.5 mg, Inhaled alprazolam 1 mg, Inhaled alprazolam 2 mg, Oral alprazolam 1 mg, Oral alprazolam 2 mg, Oral alprazolam 4 m, Oral alprazolam 2 mg qualifying session, Oral placebo qualifying session; Drug
Lead sponsor: Nova Pneuma Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Panic Disorder
Interventions: alprazolam XR; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004
U.S. locations: 47
States / cities: Little Rock, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 43 more

Conditions: Type 1 Diabetes
Interventions: Alprazolam, control group; Drug · Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Panic Disorder
Interventions: placebo, alprazolam XR; Other · Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004
U.S. locations: 3
States / cities: Eugene, Oregon • San Antonio, Texas • Middleton, Wisconsin

Conditions: Abuse Potential
Interventions: Placebo, Alprazolam 2 mg, Gabapentin Enacarbil Immediate Release (GE-IR) 200 mg, Gabapentin Enacarbil Immediate Release (GE-IR) 450 mg, Gabapentin Enacarbil Immediate Release (GE-IR) 700 mg; Drug
Lead sponsor: Arbor Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Recreational Drug Use, Prescription Drug Abuse (Not Dependent)
Interventions: Lasmiditan, Alprazolam, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy Volunteers
Interventions: Soticlestat 300 mg, Soticlestat 600 mg, Soticlestat 900 mg, Alprazolam, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy
Interventions: ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG, NIRAVAM TM 2 mg orally disintegrating tablets, single dose; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Cannabis Use Disorder
Interventions: THC, Alprazolam, Placebo oral capsule, CBD; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy Volunteer
Interventions: Alprazolam Placebo, Cenobamate placebo, Alprazolam, Cenobamate; Drug
Lead sponsor: SK Life Science, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Cataract Surgery, Sedation, Cognition Function, Perioperative Care, Older Adults
Interventions: Alprazolam, Midazolam; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 65 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Chronic Migraine Without Aura, Intractable, Migraine With Typical Aura, Migraine Disorders
Interventions: Dexamethasone, Lidocaine, Thiamine cohort; Combination Product
Lead sponsor: Corona Doctors Medical Clinics, Inc.; Other
Eligibility: 10 Years to 90 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Corona, California

Conditions: Type 1 Diabetes
Interventions: Alprazolam, Placebo; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 50 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

A Study to Evaluate the Use of Extended Release Alprazolam in the Treatment of Adolescents With Panic Disorder

Validation of the Drug Impaired Driving Scenario (DIDS) on the CRCDS-miniSim

A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Non-Fasting Conditions

Staccato Alprazolam Abuse Liability

A Study To Assess the Safety of Extended Release Alprazolam for the Treatment of Adolescents With Panic Disorder or Anxiety With Panic Attacks

Hypoglycemia Associated Autonomic Failure in Type 1 DM, Q2

A Study to Assess the Long-term Use of Alprazolam Extended Release (XL) in the Treatment of Adolescents With Panic Disorder

An Abuse Potential Study of Orally Administered HORIZANT in Healthy, Non-dependent, Recreational Drug Users

A Study of the Abuse Potential of Lasmiditan in Participants Who Are Recreational Drug Users

A Study of Soticlestat in Healthy Adult Nondependent Recreational Drug Users With Central Nervous System (CNS) Depressant Experience

A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Fasting Conditions

Evaluation of the Effects of Cannabidiol (CBD) Compared to Delta-9-Tetrahydrocannabinol (THC) and Alprazolam

A Study of the Abuse Liability Potential of Cenobamate in Recreational Drug Users

Oral vs IV Sedation for Cataract Surgery in Older Adults

Treatment of Chronic Migraine Headaches.

Mechanisms of Hypoglycemia Associated Autonomic Dysfunction Question 2